Specialist Inpatient Detoxification from Gabapentinoids: Clinical and Demographic Characteristics and Predictors of Outcome.

Authors

Aansha Priyam, Andrew Hill, Mostafa Abdellatif, Shelly Ann, Rathi Ravindrarajah, Nay Myo, Nanda Ko, Chris Daly, Stephen J Kaar

Published in

Journal of psychoactive drugs. Pages 1-8. Jun 28, 2026. Epub Jun 28, 2026.

Abstract

Gabapentinoids are increasingly implicated in drug-related deaths, and little is known about the harms of dependence or detoxification outcomes. Abrupt cessation is associated with adverse events, such as seizures, yet no standardized withdrawal scales or treatment regimens exist. This study describes the clinical and demographic characteristics of people undergoing specialist inpatient gabapentinoid detoxification in a large, regional unit in Manchester, United Kingdom, and explores predictors of treatment outcome. The sample included all patients (n = 38) admitted for gabapentinoid detoxification between years 2017-2022. Clinical data were analyzed using a retrospective observational cohort design to explore associations between baseline characteristics and outcomes. We hypothesized that people undergoing multiple detoxifications and/or detoxification for illicit gabapentinoid use would be more likely to have negative outcomes. This is the largest cohort undergoing inpatient detoxification from gabapentinoids studied till date. The majority were male, White British, unemployed, straight, with a mean age of 38.9 (SD = 8.9), and required detoxification from multiple substances (n = 35). The majority completed detoxification successfully. Relapse (p < .001), complications (p = .001), personality disorders (p = .034), a concurrent benzodiazepine (p = .011) or opioid detoxification (p = .025) were significantly associated with an incomplete detoxification. Illicit use of pregabalin, and multiple concurrent detoxifications were not related to outcomes. Further research is needed to optimize treatment.

PMID:
42366702
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.